Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus platinum doublet chemotherapy with concurrent chemoradiotherapy and camrelizumab maintenance in unresectable stage III NSCLC
ChiCTR2200060876Phase 2Recruiting
- Sponsor
- Cancer Center of Guangzhou Medical University
- Start
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in non-small cell lung cancer (NSCLC), sponsored by Cancer Center of Guangzhou Medical University. Primary endpoint: Objective response rate. Started Jun 2022; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2200060876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060876.